Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

New England Journal of Medicine

Volumn 352, Issue 25, 2005, Pages 2598-2608

  Keymeulen, Bart ^a,i   Vandemeulebroucke, Evy ^a   Ziegler, Anette G ^b   Mathieu, Chantal ^c   Kaufman, Leonard ^a   Hale, Geoff ^d   Gorus, Frans ^a   Goldman, Michel ^e   Walter, Markus ^b   Candon, Sophie ^f   Schandene, Liliane ^e   Crenier, Laurent ^e   De Block, Christophe ^g   Seigneurin, Jean Marie ^h   De Pauw, Pieter ^a   Pierard, Denis ^a   Weets, Ilse ^a   Rebello, Peppy ^d   Bird, Pru ^d   Berrie, Eleanor ^d   Frewin, Mark ^d   Waldmann, Herman ^d   Bach, Jean François ^f   Pipeleers, Daniel ^a   Chatenoud, Lucienne ^f   more..

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b Klinikum Schwabing   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ERASME HOSPITAL   (Belgium)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h HÔPITAL MICHALLON   (France)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CD3 ANTIGEN; GLUCAGON; GLUCOSE; IMMUNOGLOBULIN G1 ANTIBODY; INSULIN; PLACEBO; ANTIDIABETIC AGENT; AUTOANTIBODY; IMMUNOGLOBULIN G;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EPSTEIN BARR VIRUS; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GLUCOSE CLAMP TECHNIQUE; HEADACHE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METABOLISM; MONONUCLEOSIS; MULTICENTER STUDY; MYALGIA; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SIDE EFFECT; SORE THROAT; BIOSYNTHESIS; BLOOD; CHILD; GLUCOSE BLOOD LEVEL; HERPES VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PANCREAS ISLET; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ANTIGENS, CD3; AUTOANTIBODIES; BLOOD GLUCOSE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE CLAMP TECHNIQUE; HERPESVIRIDAE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN G; INSULIN; ISLETS OF LANGERHANS; MALE;

EID: 20544443927     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043980     Document Type: Article

References (31)

1. Like AA, Rossini AA, Guberski DL, Appel MC, Williams RM. Spontaneous diabetes mellitus: reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science 1979;206:1421-3.
2. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre doubleblind trial. Lancet 1986;2:119-24.
3. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223:1362-7.
4. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988;37:1574-82.
5. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:123-7.
6. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158:2947-54.
7. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-betadependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-8.
8. Chatenoud L. CD3-specific antibodyinduced active tolerance: from bench to bedside. Nat Rev Immunol 2003;3:123-32.
9. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49:697-702.
10. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;47:606-8.
11. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994;57:1537-43.
12. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68:608-16.
13. Routledge EG, Lloyd I, Gorman SD, Clark M, Waldmann H. A humanized monovalent CD3 antibody which can activate homologous complement. Eur J Immunol 1991;21:2717-25.
14. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-11.
15. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999;68:1632-7.
16. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in newonset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8.
17. Decochez K, Keymeulen B, Somers G, et al. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Diabetes Care 2000;23:1072-8.
18. Phillips J, Drumm A, Harrison P, et al. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy 2001;3:233-42.
19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
20. Faber OK, Binder C. C-peptide response to glucagon: a test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26:605-10.
21. Gerlo E, Gorus F. Calibration of ionexchange HPLC measurements of glycohemoglobin: effect on interassay precision. Clin Chem 1997;43:2353-7.
22. Brengel-Pesce K, Morand P, Schmuck A, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol 2002;66: 360-9.
23. Decochez K, Tits J, Coolens JL, et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. Diabetes Care 2000;23:838-44.
24. Van der Auwera BJ, Schuit FC, Weets I, Ivens A, Van Autreve JE, Gorus FK. Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for future prevention studies. Hum Immunol 2002;63:40-50.
25. Bachelez H, Flageul B, Dubertret L, et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun 1998;11:53-62.
26. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-55.
27. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002;260:285-302.
28. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
29. Hislop AD, Gudgeon NH, Callan MF, et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 2001;167:2019-29.
30. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003;52:1059-65. [Erratum, Diabetes 2003; 52:2643.]
31. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982;12:979-82.